## Elisa Roca

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1257136/publications.pdf

Version: 2024-02-01

		331538	395590
55	1,245	21	33
papers	citations	h-index	g-index
55	55	55	2368
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy. European Radiology, 2013, 23, 3450-3455.	2.3	107
2	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Advances in Therapy, 2020, 37, 1145-1155.	1.3	102
3	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. British Journal of Cancer, 2019, 120, 57-62.	2.9	68
4	Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. Cancer Treatment Reviews, 2017, 59, 117-122.	3.4	61
5	MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. European Journal of Endocrinology, 2017, 177, R231-R248.	1.9	58
6	Malignant Pleural Mesothelioma: From the Bench to the Bedside. Respiration, 2012, 83, 481-493.	1.2	48
7	CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer. Radiologia Medica, 2021, 126, 786-794.	4.7	46
8	Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy. Radiologia Medica, 2019, 124, 877-886.	4.7	42
9	Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2018, 16, 165-175.e2.	0.9	41
10	Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. Lung Cancer, 2019, 127, 12-18.	0.9	40
11	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treatment Reviews, 2018, 71, 76-87.	3.4	38
12	Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. Journal of Oncology, 2009, 2009, 1-8.	0.6	35
13	Positive FDG-PET/CT of the Pleura Twenty Years after Talc Pleurodesis: Three Cases of Benign Talcoma. Respiration, 2014, 87, 243-248.	1.2	34
14	Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. Expert Review of Anticancer Therapy, 2018, 18, 1125-1133.	1.1	34
15	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. Bone, 2017, 97, 147-152.	1.4	33
16	CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). European Journal of Radiology, 2018, 109, 130-135.	1.2	33
17	Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions. Oncotarget, 2016, 7, 3357-3366.	0.8	31
18	Palbociclib inhibits proliferation of human adrenocortical tumor cells. Endocrine, 2018, 59, 213-217.	1.1	28

#	Article	IF	CITATIONS
19	Elastic properties of the ascending aorta in patients with $\hat{l}\pm 1$ -antitrypsin deficiency (Z homozygotes). Heart, 2012, 98, 1354-1358.	1.2	25
20	Topoisomerase $2\hat{l}_{\pm}$ and thymidylate synthase expression in adrenocortical cancer. Endocrine-Related Cancer, 2017, 24, 319-327.	1.6	24
21	Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. Journal of Neurosurgical Sciences, 2019, 63, 458-467.	0.3	22
22	Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma. Endocrine, 2018, 61, 169-172.	1.1	21
23	Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions. Clinical Respiratory Journal, 2018, 12, 1011-1016.	0.6	20
24	18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients. Lung Cancer, 2013, 79, 187-190.	0.9	19
25	Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study. Oncology, 2018, 94, 10-15.	0.9	19
26	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonâ€"small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer, 2020, 21, 1-14.e3.	1.1	19
27	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. Neuroendocrinology, 2021, 111, 475-489.	1.2	19
28	Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer. Cells, 2020, 9, 291.	1.8	18
29	Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?. Respiration, 2015, 89, 558-564.	1.2	16
30	Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity. Pharmacology, 2017, 100, 261-268.	0.9	14
31	Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. In Vivo, 2018, 32, 159-164.	0.6	14
32	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. Cells, 2020, 9, 1828.	1.8	13
33	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. Expert Opinion on Biological Therapy, 2020, 20, 319-326.	1.4	12
34	Echocardiographic evaluation in subjects with î± <sub>1</sub> â€Antitrypsin deficiency. European Journal of Clinical Investigation, 2015, 45, 949-954.	1.7	11
35	How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 25-34.	1.0	11
36	Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study. European Journal of Radiology, 2019, 118, 251-256.	1.2	11

#	Article	IF	CITATIONS
37	The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. Oral Oncology, 2021, 114, 105128.	0.8	11
38	Effects of CPAP on systemic hypertension in OSAH: A monocentric, observational, cohort study. Respiratory Medicine, 2012, 106, 1329-1334.	1.3	10
39	Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 729-742.	1.4	7
40	Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma. Supportive Care in Cancer, 2018, 26, 2929-2935.	1.0	6
41	Regression of advanced neuroendocrine tumors among patients receiving placebo. Endocrine-Related Cancer, 2017, 24, L13-L16.	1.6	5
42	Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. Endocrine, 2019, 64, 724-726.	1.1	5
43	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. Lung Cancer, 2019, 134, 121-126.	0.9	4
44	Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues. Journal of Clinical Oncology, 2016, 34, 3709-3710.	0.8	3
45	When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?. Journal of Clinical Oncology, 2017, 35, 1487-1488.	0.8	3
46	Rate of venous thromboembolism and atrial fibrillation in a real-world case series of advanced cancer patients: the CaTEV Study. Journal of Cardiovascular Medicine, 2021, 22, 444-452.	0.6	3
47	IFN- $\hat{l}\pm$ in advanced well-differentiated neuroendocrine tumors: the neglected drug?. Future Oncology, 2018, 14, 897-899.	1.1	1
48	Targeted delivery of TNF using NGR-TNF in combination with chemotherapy as an effective and tolerable strategy in a hepatocarcinoma patient. Memo - Magazine of European Medical Oncology, 2008, 1, 43-46.	0.3	0
49	Malignant pleural mesothelioma signs and symptoms. Lung Cancer Management, 2015, 4, 205-209.	1.5	0
50	Efficacy of topic steroids in the management of asthma and chronic obstructive pulmonary disease in advanced non-small cell lung cancer patients during treatment with nivolumab. Minerva Respiratory Medicine, 2018, 57, .	0.1	0
51	Cancer of the Adrenal Gland. UNIPA Springer Series, 2021, , 933-955.	0.1	0
52	Detection of serum proteomic profile predictive for epidermal growth factor receptor tyrosine kinase inihibitors (EGFR-TKIs) in 1st line chemotherapy responders. Journal of Clinical Oncology, 2008, 26, 8091-8091.	0.8	0
53	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. Translational Cancer Research, 2018, 8, S16-S22.	0.4	0
54	The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma. Translational Cancer Research, 2018, 7, S506-S509.	0.4	0

#	Article	IF	CITATIONS
55	Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice. Annals of Translational Medicine, 2018, 6, 369-369.	0.7	O